ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,614.56
-2.70%
US Tech 100
19,010.00
0.53%
Dow Jones
41,911.71
-2.08%
Brent Oil
69.85
1.17%
Bitcoin
81,620.03
4.01%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Amarin Corp PLC (AMRN) Quote

Amarin Corp PLC

Amarin Corp PLC (AMRN)

NASDAQ
0.4652
-0.0648
(-12.23%)
Closed March 10 4:00PM
Delayed by 15 minutes
0.4652
0.00
( 0.00% )
Pre Market: 6:37AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.4652
Bid
0.3705
Ask
0.4999
Volume
21
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
191.354M
Previous Close
0.4652
Open
-
Last Trade
10
@
0.5025
Last Trade Time
04:42:08
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
411,338,131
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
306.91M
Net Profit
-59.11M

About Amarin Corp PLC

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa. Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its lead product includes Vascepa.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.amarincorp.com
Headquarters
London, Gbr
Founded
-
Amarin Corp PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMRN. The last closing price for Amarin was $0.47. Over the last year, Amarin shares have traded in a share price range of $ 0.00 to $ 0.00.

Amarin currently has 411,338,131 shares outstanding. The market capitalization of Amarin is $191.35 million.

Ask ADVFN Intelligence (AI)

AMRN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 31 2025
AMRN (-12.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 31 2025
AMRN (-12.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 31 2025
AMRN (-12.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 10 2025
AMRN (-12.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 10 2025
AMRN (-12.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 10 2025
AMRN (-12.23%)

Form 8-K - Current report
Edgar (US Regulatory)
December 18 2024
AMRN (-12.23%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

AMRN - Frequently Asked Questions (FAQ)

What is the current Amarin share price?
The current share price of Amarin is $ 0.4652
How many Amarin shares are in issue?
Amarin has 411,338,131 shares in issue
What is the market cap of Amarin?
The market capitalisation of Amarin is USD 191.35M
What is the 1 year trading range for Amarin share price?
Amarin has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the reporting currency for Amarin?
Amarin reports financial results in USD
What is the latest annual turnover for Amarin?
The latest annual turnover of Amarin is USD 306.91M
What is the latest annual profit for Amarin?
The latest annual profit of Amarin is USD -59.11M
What is the registered address of Amarin?
The registered address for Amarin is ONE NEW CHANGE, LONDON, EC4M 9AF
What is the Amarin website address?
The website address for Amarin is www.amarincorp.com
Which industry sector does Amarin operate in?
Amarin operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AWHAspira Womans Health Inc
$ 0.4044
(104.24%)
53.45M
TSVT2seventy bio Inc
$ 4.95
(76.79%)
428.28k
GMHSGamehaus Holdings Inc
$ 2.58
(52.66%)
1.13M
TNONTenon Medical Inc
$ 1.89
(51.20%)
9.5M
ADTNADTRAN Holdings Inc
$ 11.49
(35.34%)
42
MBXMBX Biosciences Inc
$ 5.01
(-44.21%)
2
JANXJanux Therapeutics Inc
$ 20.05
(-33.65%)
40
SVRASavara Inc
$ 2.01
(-24.44%)
4
SNCRSynchronoss Technologies Inc
$ 6.01
(-22.45%)
3
XXII22nd Century Group Inc
$ 1.58
(-21.39%)
5
AWHAspira Womans Health Inc
$ 0.4043
(104.19%)
53.45M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 7.85
(6.37%)
17.67M
BTOGBit Origin Ltd
$ 0.51
(7.35%)
13.69M
CUTRCutera Inc
$ 0.1551
(20.70%)
10.12M
TNONTenon Medical Inc
$ 1.89
(51.20%)
9.5M

AMRN Discussion

View Posts
hayward hayward 11 hours ago
FlyFishingStocks

Since Tesla also went down close to 25% Inc after hours are they going to 0 ? Many days after you said we would follow the market down but did not where were you then ? Seems you post only when the market fits your predictions IMO

Michael
👍️ 3
Jasbg Jasbg 11 hours ago
BBI, With you all the way here'. Where we are (in value) - we just have to trust/believe that Sarissa/Denner have a plan.

This is 'What They Do' - how Denner made his Business - Making turnarounds in the Market' - against experts expectations'.
------------------------------------------------

Truth is that Amarin and Vascepa/Vazkepa is even further out than Trump' - aiming to concur this Planet - so no reason to Give up Hope - Yet 🙂
👍️0
FlyFishingStocks FlyFishingStocks 11 hours ago
Volume interaction with overhead resistance has governed price direction.

Last week I shared this chart showing double top patterns where feeble up volume (B) led to a sharp sell off on heavy volume.


The volume reliably forecasted today's outcome

Todays chart:
👍️0
Birdbrain Ideas Birdbrain Ideas 11 hours ago
I do recall the report three years ago when Amarin lost $50 million or $70 million in a quarter and it seemed that the share price was falling nonstop for two months before earnings were announced so it was clear that word had spread. This quarter, we've seen the opposite, where the stock has risen more days than not since the start of the year and volume has remained muted. I think if there was particularly bad news coming out, the company might have preannounced. Same if there was good news. Still, I guess it's possible that we lost $20 million in the Fourth Quarter. Hope not, but it's possible. And that might explain why there has been no rush to start a share buyback. Or maybe they're preparing to announce a way to get the share price over $1 that won't make investors happy. Besides the market's collapse today, fear of the unknown may have driven some sellers.
👍️0
Number sleven Number sleven 12 hours ago
JRroon , I wasn't asking a question your response was absurd.
Sleven,
👍️0
lizzy241 lizzy241 12 hours ago
proliberty, could be margin calls not for AMRN but other stocks. KIM For every seller there's a buyer.
👍️0
FlyFishingStocks FlyFishingStocks 14 hours ago
As TA forecasted, the .43 cent target was reached on the downside based on this chart I posted 1 week ago



The stock printed a new low today of .40. Wow... that is a -25% plunge intra-day.
👍️0
ProLiberty ProLiberty 14 hours ago
Agreed. And in a typical company dominated by management and a captured BOD, you might well see enrichment of insiders at expense of shareholders / a full burn of any cash. In this case, Sarissa is in full control and should be able to force further cost cuts and a sale if the best option to avoid massive cash burn.
👍️0
rosemountbomber rosemountbomber 14 hours ago
No question that it seems ridiculous. However, market is forward looking. It must think that revenue from the EU will not come fast enough to make up for losses here. Only thing I can think of that the market thinks that cash will evaporate in the future. Important to have an earnings report and CC that instills confidence that that won't happen.

I should add, that the market is sometimes pretty stupid. Huge valuations for companies that aren't making any money and many examples of stocks bashed to hell and lo and behold they resurrect.
👍️0
ProLiberty ProLiberty 15 hours ago
Hayward, it is crazy. $193m market cap with $300m cash. They could just shut down, sell inventory and IP, and hand back something like $1.00-1.50 (assuming the patent does not have a negative value).
👍️ 1
hayward hayward 15 hours ago
ProLiberty

From .53 to .40 on less then 3 million shares traded is crazy What happens when we trade 20 million in a day 0 ??

Michael
👍️0
JRoon71 JRoon71 15 hours ago
Thanks for these links, Lizzy. I'm still bullish on the new formulation...even if I'm not comfortable with what Denner is doing.
👍️0
ProLiberty ProLiberty 15 hours ago
Bit of strange after market activity... someone put in a 98k share bid at $0.4884... got filled. Then 18k shares at same price... filled. Now 73k filled at $0.4652... another 27k at $0.4652. That was after getting beaten down with two or three 200k blocks and a 400k block during normal hours.
👍️0
KnowNothingJonSnow KnowNothingJonSnow 15 hours ago
Are they selling a new drug we haven’t heard of? They can’t sell Vascepa anywhere.
👍️0
ramfan60 ramfan60 15 hours ago
They could fall much lower as you say but don't be fooled into just thinking of them as a car company........they are deep into AI and autonomous vehicles/robotics and energy......we'll see if my gamble pays off......
👍️0
lizzy241 lizzy241 15 hours ago
ziploc, please see my post above re LR-EtEPA patents.
👍️0
lizzy241 lizzy241 15 hours ago
https://register.epo.org/application?number=EP24152359&lng=en&tab=doclist
👍️0
rosemountbomber rosemountbomber 15 hours ago
No question. As much as I bitch from time to time of how management did not do its fiduciary duty, I am the most guilty party. That was the time to sell for sure.
👍️0
alwayswatching1 alwayswatching1 15 hours ago
Agree with the first part. Definitely don’t agree with the lottery ticket part. Amarin has a history of repeating itself and it will again. The stock is due for a launch to where is the question.
👍️0
lizzy241 lizzy241 15 hours ago
For those who follow patent activity, see below 5/23/24 US20240165066A1 EU 12/04/24 #EP2374613A
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023146984
FDC status EP4338805 EP4342546
https://register.epo.org/application?number=EP24152348&tab=main
👍️0
KnowNothingJonSnow KnowNothingJonSnow 15 hours ago
Holding after label approval was the opposite of what we all should have done. Could have sold for profit and never thought about this shitco again. But alas, I can’t sell and now holding onto a lottery ticket that very likely never hits.
👍️0
rosemountbomber rosemountbomber 15 hours ago
Not to mention that growth could actually slow. Half the population (typical buyers) now shunning the brand and the other half of the population prefers petroleum based locomotion.
👍️0
exwannabe exwannabe 16 hours ago
I've been adding shares of TSLA....... once the Musk Derangement Syndrome therapies kick in, the stock will head north.
They have a PE over 100 with growth stalled in an industry with a PE under 15%.

TSLA could very realistically fall to under $40.
👍️0
tm100 tm100 16 hours ago
Seems more typical for this to run up a week before quarterly report, then crash after the report. Looks like a different scenario at the moment
👍️0
alwayswatching1 alwayswatching1 16 hours ago
Just the last bit of braindead retail getting out before the turnaround here. Always a few that will do the opposite of what they should. This is the last great buy opportunity IMO. Save this post!
👍️0
Birdbrain Ideas Birdbrain Ideas 18 hours ago
I've noticed that as well with my bios. If AMRN turns around today, I'm up nicely overall on a day when the market is getting killed. Hoping this signals a turnaround in the depression that has hit small pharmaceuticals in particular over the past few years.
👍️0
seve333 seve333 18 hours ago
Jron the the short is over on stockwits showing his full blown TDS. Now he has taken to trashing Trump The dude is beyond comical.
👍️ 1
ramfan60 ramfan60 19 hours ago
I've been adding shares of TSLA....... once the Musk Derangement Syndrome therapies kick in, the stock will head north.
👍️ 1
rosemountbomber rosemountbomber 20 hours ago
Yep. I have a couple of bios that are turning green on a huge red day. Of course a bunch of other stuff in the red.
👍️0
ramfan60 ramfan60 20 hours ago
Doesn't it seem like we time our quarterly results to be released in the middle of every market crash?
👍️0
Birdbrain Ideas Birdbrain Ideas 20 hours ago
My ray of hope is that Denner, though he might lack some knowledge that would be more helpful in growing the company, may have superior skills and contacts at putting together a buyout in the next year or two that can benefit all of us. I found it encouraging that he got rid of his hand-picked guy to run the company and turned it back over to people who have run Amarin for a decade or more. I haven't given up on him at all, especially since he's steering the ship right now. I'm sure a lot of people were critical of JT when he was running the company, since he was an accountant. Maybe an accountant was just what we needed then. Perhaps his slickest move, which eliminated the prospect of bankruptcy, came when he raised over a half billion dollars six months before Judge Du gave the company a near-fatal blow.
👍️ 1
JRoon71 JRoon71 20 hours ago
Not sure what you're asking
👍️0
Number sleven Number sleven 21 hours ago
JRoon, ?
Sleven,
👍️0
JRoon71 JRoon71 21 hours ago
Sleven, that's certainly possible. Of course, we don't know that. There's 7 generics selling IPE, each with their own economics. What would actually make things worse for us is if several of them stop selling IPE, and thus handing more market share to the ones that are left.

But let's hope that the tariffs can put some kind of dent in their margins.
👍️0
ziploc_1 ziploc_1 22 hours ago
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

I am looking forward to some discussion of Lr Et EPA at the C.C.
👍️ 3
couldbebetter couldbebetter 22 hours ago
North, Given that Alex Denner essentially sold
The Medicines Company to NVS, one would hope
his relationship with NVS is such that they would at
least listen to what he may propose, and would be
able to disclose to NVS the new formulation that
could be the game changer...Most especially if NVS
were to take the idea and run with it!
👍 2
rosemountbomber rosemountbomber 22 hours ago
Different space but Indian Sun Pharma buying Checkpoint Therapeutics.   Not sure if it has anything to with tariffs.  Probably not as Checkpoint had some positive news on their cancer drug.  But they have been losing money every quarter - still pre-clinical co. 

https://finance.yahoo.com/news/top-india-drugmaker-sun-buy-034544292.html
👍️0
Number sleven Number sleven 24 hours ago
JRoon, At the moment our patents aren't providing any protection. That's the point behind the lawsuit. The only reason that Amarin has been able to maintain market share, is by negotiating better pricing with providers. The fact that they have been fairly successful is important. It tells us that our generic competition can't easily drop their wholesale prices below ours. If the generic companies are suddenly faced with a 10-20 percent increase in production cost, it will put them at a disadvantage.
Sleven,
👍️ 4
JRoon71 JRoon71 1 day ago
1. Because they own the patent for CVD

2. Pricing flexibility

👍️0
ramfan60 ramfan60 2 days ago
Well Rose, at the time we had just published the results of a 5 year landmark study that showed if you stack V on top of the #1 drug in the world (Statins not Viagra), you reduce the incidence of the #1 cause of death in the world. So it's hard to gauge whether the asking price was unrealistic. We had the whole market to ourselves until we lost it in the US to the corrupt system we have....... but all is not lost just yet....we have the EU until at least 2039 and a BP could definitely scale this thing by acquiring AMRN and then Doging the SG&A line...... with lower expenses and higher volume, you can reduce the price and it would then become just what JT envisioned....a volume play. Let's gettir done......
👍️ 2
rosemountbomber rosemountbomber 2 days ago
And we haven't had too many of those lately SD.  Hard to believe that V wouldn't be of some value to BP.  My concern for an acquisition to happen is bloated value expectation by the seller.  There had to be some interest from BP around the time of R-I but speculation is that JT spooked them with an unrealistic asking price.  We will never know for sure.  Hopefully Denner can make a deal.
👍️ 1
Skipperdog11 Skipperdog11 2 days ago
Now that is a beautiful thought!
👍 1
CaptBeer CaptBeer 2 days ago
https://www.linkedin.com/feed/update/urn:li:activity:7304103848942456832?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7304103848942456832%2C7304580635988307971%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287304580635988307971%2Curn%3Ali%3Aactivity%3A7304103848942456832%29
👍️0
ziploc_1 ziploc_1 2 days ago
North....Ordinarily we should hope that AMRN has increased earnings to enhance the stock price...but at this juncture, what matters even more is the occurance of events that would interest a BP in buying the company.
👍 1 👍️ 1
Number sleven Number sleven 2 days ago
JRoon, How has Amarin been able to maintain market share?
Sleven,
👍️0
Number sleven Number sleven 2 days ago
Kiwi, That site updates periodically. Without a subscription you can only look so far back in time. When any of the generic companies import supply, it shows up. I have been monitoring importation of icosapent ethyl for about three years.
Sleven,
👍️ 1
north40000 north40000 2 days ago
Amarin could be a named, wholly-owned subsidiary of Novartis by June 27, 2025. The co-sponsor, co-exhibitor evidence depicted in DMC8's message supports that proposition, now more than mere speculation, IMO.
👍 3
Whalatane Whalatane 2 days ago
Epic , who I've never heard of importing via Wuhan China ?
Based on available evidence, Hikma Pharmaceuticals and Teva Pharmaceuticals are the most likely candidates for selling the most generic Vascepa in the U.S. as of now, with Hikma having an edge due to its first-mover advantage and Teva potentially leading through sheer market reach.

Kaiser is buying from Teva now
Kiwi
👍️0
lizzy241 lizzy241 2 days ago
Sleven, do we know the tariffs will be 20%? No one knows; the last I heard was "reciprocal" tariffs will be imposed. I guess we'll get a better idea during the conf call?
👍️0
rosemountbomber rosemountbomber 2 days ago
I tend to agree with that JRoon, particularly if it is a large Generic.
👍️0

Your Recent History

NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads